Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Level 5 - mechanism / opinion, no new human data
Narrative review of literature without systematic review or meta-analysis methodology
PubMed 19025432 · doi:10.1592/phco.28.12.1511
What was done
The authors conducted a narrative literature search of MEDLINE (1986–2008) and relevant citation lists to summarize evidence on the risk of metabolic syndrome, diabetes mellitus, and coronary artery disease in men undergoing medical or surgical androgen deprivation therapy (ADT) for prostate cancer.
What was found
No numerical estimates, effect sizes, or study counts are reported in the abstract. The authors report that ADT (particularly LHRH agonists such as goserelin, histrelin, leuprolide, and triptorelin) induces body composition changes, hyperlipidemia, insulin resistance, metabolic syndrome, and acute coronary syndrome via testosterone depletion, with cardiometabolic risks becoming evident within months of starting therapy and persisting after discontinuation.
Why it matters
It highlights the need for clinicians to recognize the rapid onset of cardiometabolic complications in patients starting ADT and to implement routine monitoring and preventive lifestyle counseling.
Limits
The paper is a narrative literature review rather than a systematic review or meta-analysis. The abstract provides no quantitative data, sample sizes, or formal risk evaluations.
Cited by
- supports Androgen deprivation therapy in prostate cancer patients typically causes increased fat mass, loss of muscle mass, elevated cardiovascular disease risk, and insulin resistance or diabetes.